XSHE
002223
Market cap3.78bUSD
Jul 10, Last price
26.02CNY
1D
1.84%
1Q
-20.18%
Jan 2017
25.82%
IPO
1,392.49%
Name
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd., formerly known as Yuwell Medical, was established in 1998 and is headquartered in Shanghai, China. The company operates globally, manufacturing and distributing a diverse array of medical devices in both domestic and international markets. Its extensive product catalog includes sophisticated respiratory therapy solutions, such as ventilators, humidifiers, oxygen generators, nebulizers, and advanced non-invasive ventilator data management systems. Yuwell also offers comprehensive chronic disease monitoring systems, featuring sphygmomanometers, blood glucose meters, pulse oximeters, thermometers, stethoscopes, alongside general practice diagnostic tools and in-hospital blood glucose management platforms. Furthermore, the company provides cutting-edge imaging diagnosis and treatment solutions, including ultrasound diagnostic imaging, interventional, and minimally invasive technologies. Its offerings extend to infection control and disinfection products, as well as specialized ophthalmology and vision care items like microscopes, eye surgical instruments, ophthalmoscopes, synoptophores, and keratometers. Defibrillator monitors are also part of their product range. Additionally, Yuwell supplies a broad spectrum of durable medical equipment and consumables, encompassing basic and microsurgical tools, instruments for ENT and orthopedics, endoscopic devices, dental appliances, acupuncture and electronic acupuncture products, absorbable sutures, and venous indwelling needles.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||